Media coverage about LivaNova (NASDAQ:LIVN) has trended somewhat positive this week, according to Accern. Accern rates the sentiment of media coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. LivaNova earned a media sentiment score of 0.10 on Accern’s scale. Accern also assigned news articles about the company an impact score of 45.0853440551505 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Shares of LivaNova (NASDAQ:LIVN) traded down $1.03 during midday trading on Thursday, hitting $81.05. The stock had a trading volume of 267,900 shares, compared to its average volume of 342,671. LivaNova has a 1-year low of $45.67 and a 1-year high of $88.56. The company has a quick ratio of 1.42, a current ratio of 2.03 and a debt-to-equity ratio of 0.04. The company has a market cap of $3,910.00 and a P/E ratio of 21.61.
LivaNova (NASDAQ:LIVN) last issued its quarterly earnings results on Thursday, November 2nd. The company reported $0.93 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.76 by $0.17. LivaNova had a return on equity of 9.33% and a net margin of 4.63%. The business had revenue of $309.70 million during the quarter, compared to the consensus estimate of $301.22 million. During the same period in the previous year, the business earned $0.78 EPS. The business’s quarterly revenue was up 4.9% on a year-over-year basis. research analysts forecast that LivaNova will post 3.24 EPS for the current year.
A number of equities analysts have issued reports on LIVN shares. Piper Jaffray Companies reaffirmed a “buy” rating and issued a $85.00 target price on shares of LivaNova in a research report on Friday, November 3rd. Jefferies Group upped their target price on LivaNova from $80.00 to $91.00 and gave the company a “buy” rating in a research report on Friday, November 3rd. Needham & Company LLC upped their target price on LivaNova from $83.00 to $89.00 and gave the company a “buy” rating in a research report on Friday, November 3rd. ValuEngine raised LivaNova from a “hold” rating to a “buy” rating in a research report on Thursday, November 2nd. Finally, Zacks Investment Research raised LivaNova from a “hold” rating to a “buy” rating and set a $89.00 target price on the stock in a research report on Thursday, November 9th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and five have given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $79.71.
In related news, Director Alfred J. Novak sold 2,000 shares of the company’s stock in a transaction on Wednesday, November 22nd. The stock was sold at an average price of $85.77, for a total transaction of $171,540.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Hugh M. Morrison sold 1,830 shares of the company’s stock in a transaction on Wednesday, November 29th. The stock was sold at an average price of $88.00, for a total value of $161,040.00. The disclosure for this sale can be found here. Insiders sold a total of 6,830 shares of company stock valued at $569,350 over the last quarter. Company insiders own 0.28% of the company’s stock.
WARNING: This piece was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark laws. The legal version of this piece can be accessed at https://www.dispatchtribunal.com/2018/01/11/livanova-livn-earns-coverage-optimism-rating-of-0-10.html.
LivaNova PLC is a medical device company focused on the development and delivery of therapeutic solutions. The Company’s segments include Cardiac Surgery, Cardiac Rhythm Management, Neuromodulation and Other. The Cardiac Surgery segment is engaged in the development, production and sale of cardiovascular surgery products.
Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.